EQUILLIUM, INC. (EQ) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$5.16M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$5.61M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$4.58M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$6.23M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$5.16M | (m) | (m) | (m) | $71.00K* | -$4.11M* | (m) | (m) | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$5.61M | (m) | (m) | (m) | $3.00K | -$4.30M | (m) | (m) | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$4.58M | (m) | (m) | (m) | $0.00* | -$8.43M* | (m) | (m) | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$6.23M | (m) | (m) | (m) | $0.00* | -$3.01M* | (m) | (m) | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$8.87M | (m) | (m) | (m) | $4.00K | -$8.17M | (m) | (m) | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$679.00K | (m) | $12.16M | (m) | $0.00* | -$7.66M* | (m) | (m) | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$100.00K | (m) | $13.85M | (m) | $62.00K* | $730.00K* | (m) | (m) | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$2.79M | (m) | $10.69M | (m) | $19.00K | -$8.80M | (m) | (m) | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$3.62M | (m) | $8.87M | (m) | (m) | -$1.91M* | (m) | (m) | (m) | $496.00K |
| 2023-06-30 | Reported | (m) | -$3.59M | (m) | $9.12M | (m) | (m) | -$6.21M* | (m) | (m) | (m) | $8.00K |
| 2023-03-31 | Reported | (m) | -$4.11M | (m) | $8.88M | (m) | (m) | -$8.00M | (m) | (m) | (m) | $60.00K |
| 2022-09-30 | Reported | (m) | -$13.24M | (m) | (m) | (m) | $0.00* | -$13.06M* | (m) | (m) | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$13.55M | (m) | (m) | (m) | $54.00K* | -$11.26M* | (m) | (m) | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$37.33M | (m) | (m) | (m) | $223.00K | -$12.13M | (m) | (m) | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$9.86M | (m) | (m) | (m) | $34.00K* | -$7.01M* | (m) | $6.96M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$8.84M | (m) | (m) | (m) | (m) | -$6.99M* | (m) | $5.99M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$8.70M | (m) | (m) | (m) | (m) | -$7.94M | (m) | $5.88M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$6.52M | (m) | (m) | (m) | $157.00K* | -$4.92M* | (m) | $4.22M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$6.61M | (m) | (m) | (m) | $0.00* | -$5.08M* | (m) | $3.89M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$7.45M | (m) | (m) | (m) | $15.00K | -$6.37M | (m) | $4.71M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$6.32M | (m) | (m) | (m) | $0.00* | -$4.70M* | (m) | $4.18M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$6.44M | (m) | (m) | (m) | $45.00K* | -$4.76M* | (m) | $4.25M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$6.35M | (m) | (m) | (m) | $11.00K | -$4.46M | (m) | $3.76M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$2.23M | (m) | (m) | (m) | $3.00K* | -$1.64M* | (m) | $1.22M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$1.13M | (m) | (m) | (m) | $17.00K* | -$1.17M* | (m) | $540.00K | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$1.04M | (m) | (m) | (m) | $5.00K | -$889.00K | (m) | $663.00K | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$83.71K | (m) | (m) | (m) | (m) | (m) | (m) | $49.95K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$23.63M | (m) | (m) | (m) | $48.00K | -$22.75M | (m) | (m) | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$8.27M | (m) | $41.09M | (m) | $85.00K | -$19.03M | (m) | (m) | (m) | $361.00K |
| 2023-12-31 | Reported | (m) | -$14.52M | (m) | $36.08M | (m) | $50.00K | -$21.78M | (m) | $37.04M | (m) | $580.00K |
| 2022-12-31 | Reported | (m) | -$62.08M | (m) | $15.76M | (m) | $279.00K | -$8.73M | (m) | $37.55M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$37.79M | (m) | (m) | (m) | $57.00K | -$32.08M | (m) | $26.38M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$29.55M | (m) | (m) | (m) | $202.00K | -$24.62M | (m) | $19.38M | (m) | $0.00 |
| 2019-12-31 | Reported | (m) | -$26.73M | (m) | (m) | (m) | $74.00K | -$22.95M | (m) | $17.64M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$8.62M | (m) | (m) | (m) | $35.00K | -$7.53M | (m) | $4.94M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |